Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-09 · accession 0000875320-24-000043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-13 | 2024-02-12 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $420.24 | -4,295 | 75.7K | -5% | -$1.80M | |
| 2024-02-13 | 2024-02-09 | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $422.74 | -3,177 | 80.0K | -4% | -$1.34M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-12 | S | D | 4,295 | $420.24 | 75,718 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-09 | F | D | 3,177 | $422.74 | 80,013 | D | — | — |